MAPK3 and chronic myelogenous leukemia, BCR-ABL1 positive: Rao et al. demonstrated that alvespimycin treatment inhibited activated TRKA and its downstream signaling through p-AKT and p-ERK1/2, resulting in apoptosis of cell lines and primary human AML and CML cells [27].